Fifty-five basal cell carcinomas treated with topical imiquimod: Outcome at 5-year follow-up [2]

Archives of Dermatology

Volumn 143, Issue 2, 2007, Pages 266-268

  Vidal, David ^a   Matías Guiu, Xavier ^b   Alomar, Agustín ^b  

^a HOSPITAL DOS DE MAIG   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

AGED; BASAL CELL CARCINOMA; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG MECHANISM; FEMALE; FOLLOW UP; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; TOPICAL TREATMENT; TREATMENT OUTCOME; TUMOR BIOPSY;

ADMINISTRATION, CUTANEOUS; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 33847145490     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.2.266     Document Type: Letter

References (10)

1. Weedon D. Tumors of the epidermis: basal cell carcinoma. In: Weedon D, ed. Skin Pathology. London, England: Churchill Livingstone, Harcourt Publishers; 1997:647-651.
2. Vidal D, Matias-Guiu X, Alomar A. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma. Clin Exp Dermatol. 2004;29:518-525.
3. Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 1999;41:1002-1007.
4. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial BCC: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol. 2001;44:807-813.
5. Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial BCC: a double-blind, randomized, vehicle controlled study. J Am Acad Dermatol. 2002;47:390-398.
6. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50:722-733.
7. Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005;152:939-947.
8. Sterry W, Ruzicka T, Herrera E, et al. Imiquimod 5% cream for the treatment of superficial and nodular BCC: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol. 2002;147:1227-1236.
9. Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular BCC: comparison of dosing regimens. Arch Dermatol. 2002;138:1165-1171.
10. Gollnick H, Guillen C, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe. Eur J Dermatol. 2005;15:374-381.